Fifth Circuit Impax Decision Validates FTC’s Post-Actavis Approach to Reverse Payments

Published date21 April 2021
Subject MatterFTC,Patent Litigation,Patent Infringement,Monopolization,Pharmaceutical Industry,Patents,Settlement
AuthorWilliam Cavanaugh, Jr.,Amy Vegari,Jake Walter-Warner
Law FirmPatterson Belknap Webb & Tyler LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT